Higher Donor Age and Severe Microvascular Inflammation Are Risk Factors for Chronic Rejection After Treatment of Active Antibody-Mediated Rejection

Transpl Int. 2024 Feb 2:37:11960. doi: 10.3389/ti.2024.11960. eCollection 2024.

Abstract

Recent developments in intensive desensitization protocols have enabled kidney transplantation in human leukocyte antigen (HLA)-sensitized recipients. However, cases of active antibody-mediated rejection (AABMR), when they occur, are difficult to manage, graft failure being the worst-case scenario. We aimed to assess the impact of our desensitization and AABMR treatment regimen and identify risk factors for disease progression. Among 849 patients who underwent living-donor kidney transplantation between 2014 and 2021 at our institution, 59 were diagnosed with AABMR within 1 year after transplantation. All patients received combination therapy consisting of steroid pulse therapy, intravenous immunoglobulin, rituximab, and plasmapheresis. Multivariable analysis revealed unrelated donors and preformed donor-specific antibodies as independent risk factors for AABMR. Five-year death-censored graft survival rate was not significantly different between patients with and without AABMR although 27 of 59 patients with AABMR developed chronic AABMR (CABMR) during the study period. Multivariate Cox proportional hazard regression analysis revealed that a donor age greater than 59 years and microvascular inflammation (MVI) score (g + ptc) ≥4 at AABMR diagnosis were independent risk factors for CABMR. Our combination therapy ameliorated AABMR; however, further treatment options should be considered to prevent CABMR, especially in patients with old donors and severe MVI.

Keywords: Banff classification; antibody-mediated rejection; graft survival; kidney transplantation; treatment outcomes.

MeSH terms

  • Antibodies*
  • Graft Rejection
  • Graft Survival
  • HLA Antigens
  • Humans
  • Inflammation / etiology
  • Kidney
  • Kidney Transplantation* / adverse effects
  • Kidney Transplantation* / methods
  • Middle Aged
  • Risk Factors

Substances

  • Antibodies
  • HLA Antigens

Grants and funding

This study was supported by KAKEN 21K16409.